Innovative Nanobody Immunoconjugate Targeting ERBB2 and MUC1 for Advanced Breast Cancer Therapy
VHH-P809 is a novel, humanized nanobody-based therapeutic candidate designed to target both erb-b2 receptor tyrosine kinase 2 (ERBB2) and mucin 1, cell surface associated (MUC1). This immunoconjugate is currently in the Biological Testing stage of development. By combining specific recognition of these two highly relevant tumor-associated antigens, VHH-P809 holds significant promise as an innovative treatment for breast cancer. Its dual-targeting strategy is intended to address critical disease pathways associated with breast cancer pathogenesis and progression, with the potential to enhance selectivity and therapeutic efficacy.
| Candidate | VHH-P809 |
| Target | erb-b2 receptor tyrosine kinase 2 (ERBB2) mucin 1, cell surface associated (MUC1) |
| Modality | humanized bispecific VHH |
| Indication | Breast Cancer |
Licensing Opportunity
VHH-P809 is currently open for out-licensing opportunities. We welcome discussions with partners interested in collaborating on its further development and commercialization in the breast cancer therapeutic space.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P809 |
Modality
VHH-P809 utilizes a codon-optimized nanobody immunoconjugate strategy, featuring an anti-human epidermal growth factor receptor nanobody fused via an a4 linker to the C-terminus of an engineered mucin-selective zinc metalloprotease derived from Escherichia coli O157:H7, and expressed in E. coli K12 cells. The nanobody format confers multiple advantages, including a single-domain structure, low molecular weight, and high tissue penetration capability, which are particularly valuable for targeting complex tumor microenvironments in breast cancer. The engineered metalloprotease component enhances tumor selectivity by recognizing mucin-rich cancer cells. Overall, this modality offers improved stability, production scalability, and the flexibility to access challenging tumor antigens.
Target
ERBB2 and MUC1 are established targets in oncology, each playing distinct but complementary roles in tumor biology. ERBB2, a cell surface receptor tyrosine kinase, is commonly overexpressed in certain breast cancer subtypes, driving cell proliferation and tumor aggressiveness. MUC1 is a heavily glycosylated transmembrane protein involved in cell signaling, adhesion, and immune modulation, and is often aberrantly expressed and glycosylated in breast cancer cells. Both ERBB2 and MUC1 are predominantly expressed in epithelial tissues, with elevated levels in malignant breast tissue. Targeting ERBB2 and MUC1 concurrently leverages the therapeutic rationale of addressing both receptor tyrosine kinase signaling and mucin-mediated pathobiology, potentially overcoming mechanisms of resistance. The dual-action profile of VHH-P809 against ERBB2 and MUC1 offers strategic advantages for precision breast cancer therapy.
Mechanism of Action
VHH-P809 exerts its function by binding selectively to ERBB2 and MUC1 on malignant cells. By blocking ERBB2, it is expected to disrupt aberrant signal transduction pathways that promote tumor cell proliferation and survival. Simultaneously, the fusion to a mucin-selective zinc metalloprotease enables targeted degradation or modification of MUC1, thereby impacting tumor microenvironment properties such as immune evasion and cellular adhesion. Nanobody technology, as exemplified by VHH-P809, also provides a promising platform for future therapeutic modalities such as antibody-drug conjugates (ADC) and bispecific formats. Through multi-target engagement and signal modulation, VHH-P809 aims to deliver enhanced anti-tumor effects and address heterogeneity within breast cancer.
Breast Cancer
Breast cancer is one of the most prevalent malignancies among women worldwide and remains a leading cause of mortality. It encompasses multiple biological subtypes, often characterized by distinct patterns of receptor expression including ERBB2 and MUC1. Diagnostic advancements have improved detection and personalized treatment; however, the disease still presents substantial clinical challenges, particularly for aggressive subtypes and cases resistant to standard therapies. Mainstream treatment modalities include surgery, chemotherapy, radiation, endocrine therapy, and increasingly, targeted and immunotherapeutic approaches. Despite progress, significant unmet needs persist, including overcoming drug resistance, minimizing side effects, and effectively treating metastatic and recurrent disease. The introduction of innovative antibodies and targeted conjugates, such as VHH-P809, holds promise to advance therapeutic efficacy and patient outcomes by offering more precise and effective targeting of malignant cells expressing ERBB2 and MUC1.